Sweden · Delayed Price · Currency is SEK Enorama Pharma AB Statistics
Total Valuation
STO:ERMA has a market cap or net worth of SEK 74.96 million. The enterprise value is 72.86 million.
| Market Cap | 74.96M |
| Enterprise Value | 72.86M |
Important Dates
The next estimated earnings date is Friday, November 20, 2026.
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:ERMA has 74.59 million shares outstanding. The number of shares has increased by 21.21% in one year.
| Current Share Class | 74.59M |
| Shares Outstanding | 74.59M |
| Shares Change (YoY) | +21.21% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 19.35% |
| Owned by Institutions (%) | n/a |
| Float | 60.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 37.63 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 36.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.21
| Current Ratio | 0.21 |
| Quick Ratio | 0.12 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -213.34% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 211.34% |
| Weighted Average Cost of Capital (WACC) | 14.32% |
| Revenue Per Employee | 361,750 |
| Profits Per Employee | -14.92M |
| Employee Count | 4 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 2.49 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.26% in the last 52 weeks. The beta is 1.83, so STO:ERMA's price volatility has been higher than the market average.
| Beta (5Y) | 1.83 |
| 52-Week Price Change | -68.26% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 0.73 |
| Relative Strength Index (RSI) | 54.49 |
| Average Volume (20 Days) | 37,040 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:ERMA had revenue of SEK 1.45 million and -59.68 million in losses. Loss per share was -0.83.
| Revenue | 1.45M |
| Gross Profit | -4.85M |
| Operating Income | -54.51M |
| Pretax Income | -59.68M |
| Net Income | -59.68M |
| EBITDA | -54.49M |
| EBIT | -54.51M |
| Loss Per Share | -0.83 |
Balance Sheet
The company has 2.10 million in cash and no debt, with a net cash position of 2.10 million or 0.03 per share.
| Cash & Cash Equivalents | 2.10M |
| Total Debt | n/a |
| Net Cash | 2.10M |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | -50.44M |
| Book Value Per Share | -0.68 |
| Working Capital | -25.88M |
Cash Flow
| Operating Cash Flow | -53.05M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 23,000 |
| Net Borrowing | 39.82M |
| Free Cash Flow | -53.05M |
| FCF Per Share | -0.71 |
Margins
| Gross Margin | n/a |
| Operating Margin | -3,767.24% |
| Pretax Margin | -4,124.46% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
STO:ERMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.21% |
| Shareholder Yield | -21.21% |
| Earnings Yield | -109.61% |
| FCF Yield | -97.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
STO:ERMA has an Altman Z-Score of -95.8 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -95.8 |
| Piotroski F-Score | 1 |